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Abstract
Introduction: We investigated associations between pre-transplant comorbidities,
length of stay (LOS) and Medicare payments for transplant hospitalization.
Material and methods: We examined United States Renal Data System for 24,963
recipients of first deceased-donor kidney transplants in 1995-2002 for whom
Medicare was the primary payer for at least a year pre-transplant. Pre-transplant
ICD-9-CM codes from claims were classified with the Charlson and Elixhauser
algorithms. Regression models for payments and LOS included: 1) baseline
recipient, donor and transplant factors from the Organ Procurement and
Transplant Network (OPTN), 2) OPTN variables and individual comorbidities and
3) OPTN variables and counts of Charlson or Elixhauser comorbidities. 
Results: Factors most strongly associated with LOS were type I diabetes, cold
ischemia time > 36 h, expanded criteria donor (ECD) and donation after cardiac
death (DCD). Except for ECD, each was associated with increased payments.
Upper respiratory disease, liver disease, peptic ulcer disease, diabetes, cancer
and other diseases were also associated with increased LOS and payments. Each
additional Charlson comorbidity increased LOS by 2.94% and payments by $471
(Elixhauser results: 1.71% for LOS, $277 for payments). Use of ECD or DCD organs
were associated with 10-15% higher LOS and 5% increased Medicare payments
for DCD.
Conclusions:  This methodology could be used to explore if Medicare
reimbursement for transplantation of higher-risk recipients and using non-
standard organs is financially adequate and to analyze related questions in
other healthcare systems.
Key words: kidney transplantation, comorbidities, lenght of stay cost.
Introduction
The analysis of the determinants of healthcare cost and reimbursement
is a recurring topic in the transplant literature given the importance of
adequate financial compensation to ensure the operation of transplant
programs and support at a national level. Reimbursement for inpatient
services by public and private payors uses a prospective approach that
pays hospitals according to the type of procedure or diagnosis. In the
United States (US), Diagnosis Related Groups (DRGs) were introduced by
Medicare in 1983 to pay for hospital inpatient services, including kidney
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transplantation. Diagnosis Related Groups-like
systems are also used in many other countries.
Diagnosis Related Groups separate patients into
similar groups based on resource utilization to allow
for a common reimbursement rate. While
prospective payment systems are needed to control
cost and foster efficiency, there are financial-risks
for providers when a single DRG is used to
reimburse for heterogeneous patient populations. 
In the US, the transplant population is evolving
towards a more severe case-mix, due for example
to the use of more marginal organs or trans  -
plantation of patients with more comorbidities 
[1-4]. Diagnosis Related Groups adjustments
compensate only for the most extreme outliers in
transplantation, such as patients costing more than
$45,000 [5]. Twenty percent of transplant payments
were in that category for Medicare between 2003
and 2006 [5]. However, a “gap” zone exists for more
severe patients that do not reach this high cost [6]
and concerns exist that current reimbursement may
not be adequate in cases such as those receiving
ECD or DCD kidneys [1-3]; while the same has been
expressed for certain types of liver transplants [7]. 
Use of an expanded criteria donor (ECD) [1],
donation after cardiac death donor (DCD) [2] and
duration of dialysis longer than one year [8] have
been associated with either inadequate payments
or longer length of stay (LOS) for the transplant
procedure admission. There are other factors that
could influence transplant procedure costs.
Comorbidities are one important factor. Comorbi  -
dities have been found to be associated with
increased hospital costs across several conditions
such as cardiovascular disease, respiratory con  -
ditions, asthma and others [9]. In transplantation,
existing evidence supports that pre-transplant
comorbidities such as history of cerebrovascular
accident and chronic obstructive pulmonary disease
(COPD) are associated with longer LOS for the
transplant procedure [8]. The DRG for tran  splan  -
tation does not allow to adjust for comor  bidities,
complications or organ quality [5].
Most of the available evidence about comor  -
bidities is derived from single center data. The
advantage of some of such studies is availability of
cost-information from hospital accounting systems;
however the samples represent only a small percent
of transplant centers. In addition, only a limited
number of comorbidities have been studied. 
The United States Renal Data System (USRDS)
captures billing claims data for Medicare-insured
transplant recipients across the country. Billing
claims are diagnosis-linked and can provide
additional evidence regarding the associations
between pre-transplant comorbidites and financial
outcomes in kidney transplantation. We examined
USRDS data for Medicare-insured kidney transplant
recipients to accomplish two major aims. First, we
determined the associations between pre-
transplant comorbidities and transplant procedure
LOS (considering LOS as a proxy for institutional
costs). Second, we estimated the associations
between Medicare payments for the transplant
procedure and pre-transplant comorbidities in
Medicare-insured patients. In both case we used
an expanded set of comorbidities compared to the
usual comorbidity information included in the
Organ Procurement and Transplantation Network
(OPTN) registry. Associations between donor organ
type, LOS and payments were also estimated.
Material and methods
Study population
This retrospective cohort study included all adult
(> 18 years) recipients of deceased-donor, first renal
only transplants from 1995-2002 for whom
Medicare was the primary insurer at the time of
transplant. Patient information was obtained from
the OPTN and included in the USRDS registry which
incorporates transplant registry information from
the OPTN. 
Comorbidity and payments and length of stay
data from claims
Comorbidity information from Medicare claims
was identified using the Medicare Part-A
institutional and Part -B physician/supplier claims
files. Primary and secondary International Classifi  -
cation of Diseases, 9th revision, clinical modification
(ICD-9-CM) diagnosis codes for each hospitalization
and physician visit during the last pre-transplant
year were considered. In order to ascertain pre-
transplant comorbidities using an observation
window of consistent duration across subjects, the
sample was limited to patients with at least one
continuous year of primary Medicare insurance
before transplant. Transplant procedure Medicare
payments and LOS were retrieved from the
transplant procedure claims identified by DRG 302.
Comorbidity summary measures
The ICD-9 CM diagnostic codes were sum  -
marized using  two comorbidity classification
systems. The Charlson [10] and Elixhauser [11]
algorithms classify diagnoses into 19 and 31 comor  -
bidity groupings, respectively. Both are widely used
measures of comorbidity in predictive models [12].
Adaptations of both indices for claims databases
were used [13]. 
Other study variables
The OPTN variables describing recipient, donor
and transplant factors were included in the
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regression models. These included recipient age,
race and body mass index (BMI) (including missing
BMI), cause of ESRD, duration of pre-transplant
dialysis, peak panel reactive antibodies (PRA) ≥ 50%,
OPTN-reported comorbidities; donor type (standard
criteria deceased, ECD, and DCD), donor age
(including missing age), race, BMI (including missing
BMI), and OPTN-reported comorbidties; number of
donor-recipient ABDR HLA mismatches (none, AB
mismatches, DR mismatches), donor-recipient
cytomegalovirus (CMV) sero-pairing, and
categorized cold ischemia time. Delayed graft
function (DGF) was excluded because it was
considered a post-transplant outcomes variable.
Immunosuppressant therapy at discharge and use
of induction therapy were also excluded. 
Statistical analysis
Associations between patient, donor and
transplant characteristics with Medicare payments
and LOS were estimated using multilevel regression
models. Multilevel models allow estimating the
effect of variables at different levels on a given
outcome. In multilevel models, the parameters of
one level can be modeled as outcomes following
a distribution in another level [14]. This reduces the
influence of the different variables to two types:
fixed effects, for which coefficients and its variances
are estimated and random effects that capture the
variability at different levels (i.e. pertaining to the
observations or to the modeled parameters). These
models are adequate to account for clustering of
observations (i.e. correlated errors) at different
levels. In this case, it was hypothesized that
clustering at the hospital level occurred, requiring
a model that can account for the correlation among
LOS and among payments at a given transplant
center. Use of ordinary regression methods in the
presence of correlated errors can produce low
(biased) standard errors of the estimates and can
show more statistically significant variables
compared to the results of a multilevel model. 
Multilevel linear regression models were built for
Medicare payments as the dependent variable
using OPTN variables and Charlson or Elixhauser
comorbidities and OPTN variables and the sum of
Charlson or Elixhauser comorbidities. Models with
LOS as the dependent variable were built for each
comorbidity classification system, containing the
same dependent variables as the Medicare
payment models. A generalized linear model with
Poisson distribution and a log link was used for LOS,
as it accounts for the discrete distribution of
hospital days. Parameter estimates were expressed
as percentage increase (or decrease) in LOS and as
a dollar change in Medicare payment versus
a reference. For dichotomous variables such as ECD
or DCD, the reference case refers to patients
without the variable of interest holding all other
variables constant. When calculating Medicare
payments and LOS in models with the sum of
Charlson (range 0-6) or Elixhauser (range 0-11)
comorbidities the results compare to patients
without comorbidities while all other recipient,
donor and transplant factors were held constant.
In all models, the intercept was modeled 
as a random effect and therefore allowed
differentiation by transplant center. All analyses
were performed in SAS 9.1 (Cary, NC). Proc Mixed
[15] was used for the Medicare payment models
and Proc Glimmix [16] was used for the LOS models. 
Results
Patient population and comorbidities
During this time period, 27,177 patients met
initial study criteria: 3,167 patients (12.7%) had
missing donor age, 846 (3.39%) had missing
recipient BMI and 879 (3.52%) lacked donor BMI.
Thus, 24,963 patients remained after excluding
patients with missing data in other variables. Most
patients were between 30 and 59 years (19,146
[77.8%]), 38,9% were male and 35.11% were African-
American. The most prevalent OPTN reported
comorbidities were hypertension (n = 18,655
[74.73%]) and diabetes (n = 7,607 [30.47%]).
Twenty-five percent of patients had 3 or more
Charlson comorbidities and twenty percent of
patients had six or more Elixhauser comorbidities.
Transplant induction therapy was used in 12,026
patients (48.18%). The most prevalent immuno  -
suppressive regimen at discharge was cyclosporine
and mycophenolate mofetil (n = 9,009, 36.09%),
with more than 90% of patients receiving steroids
at discharge (n = 23,339, 93.49%) (Table I). 
Regression estimates for transplant procedure
and longer length of stay
Organ Procurement and Transplantation
Network factors
The LOS and payments for population average
characteristics were 9.48 days and 27,594
respectively. Some of the top 10 OPTN variables
associated with highest percentage increase in LOS
and Medicare payments were common to both
outcomes and included type I diabetes as cause of
ESRD, cold ischemia time > 36 h, DCD, dialysis
duration longer than 5 years, the presence of
DR mismatches, history of myocardial infarction and
presence of functional limitations. Donor age (more
than 44 years) and unreported CMV sero-pairing
were also associated with longer LOS while Hispanic
recipient and history of Chronic Obstructive
Pulmonary Disease (COPD) were associated with
higher Medicare payments (Table II). The results of
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Variable N (%) (n = 24,963) Variable N (%) (n = 24,963)
Recipient factors Donor factors
Age Age
18-29 2,220 (8.89) < 18 3,795 (15.2)
30-44 7,395 (29.62) 18-29 4,797 (19.22)
45-59 9,801 (39.26) 30-44 5,354 (21.45)
60+ 5,547 (22.22) 45-59 5,808 (23.27)
Female gender 9,703 (38.87) 60+ 2,042 (8.18)
Racial background Unknown 3,167 (12.69)
Black 8,764 (35.11) Female gender 9,968 (39.93)
Other 1,621 (6.49) Racial background
White 14,578 (58.4) Black 3,031 (12.14)
Hispanic origin 3,248 (13.01) Other 1,421 (5.69)
Body mass index White 20,511 (82.17)
Normal 10,699 (42.86) Hispanic origin 2,709 (10.85)
Overweight 7,895 (31.63) Body mass index
Obese 5,523 (22.12) Normal 12,747 (51.06)
Unknown 846 (3.39) Overweight 6,506 (26.06)
Limits 2,103 (8.42) Obese 4,831 (19.35)
Primary cause of ESRD Unknown 879 (3.52)
Type I diabetes 2,938 (11.77) Donor cause of death
Type II diabetes 3,803 (15.23) Anoxia 2,291 (9.18)
Hypertension 6,310 (25.28) Cerebrovascular/stroke 9,789 (39.21)
Polycystic kidney disease (PKD) 1,819 (7.29) Head trauma 11,448 (45.86)
Glomeruloneprhitis 4,751 (19.03) CNS tumor 250 (1)
Other 3,090 (12.38) Other 1,185 (4.75)
Unknown 2,252 (9.02) Donor comorbidities
Pre-tx dialysis duration Hypertension 4,744 (19.0)
12-24 months 4,472 (17.91) Diabetes 855 (3.43)
24-60 months 14,612 (58.53) Alcohol abuse 4,539 (18.18)
> 60 months 5,879 (23.55) Cigarette use 9,344 (37.43)
OPTN recorded comorbidities Drug use 4,382 (17.55)
Angina 3,182 (12.75) Transplant characteristics
Arrhythmia 184 (0.74) PRA ≥ 50% 1,366 (5.47)
Congestive heart failure 1,685 (6.75) HLA mismatches
COPD 427 (1.71) No MM 1,982 (7.94)
Cerebrovascular disease 609 (2.44) No DR MM 5,609 (22.47)
Hypertension 18,655 (74.73) DR MM 17,372 (69.59)
Myocardial infarction 342 (1.37) Cold ischemia time
Diabetes 7,607 (30.47) 0-12 h 3,418 (13.69)
Peripheral vascular disease 1,560 (6.25) 13-24 h 11,991 (48.04)
Smoking history 703 (2.82) 25-36 h 6,288 (25.19)
Alcohol abuse history 144 (0.58) 36+ h 1,014 (4.06)
Undetermined 2,252 (9.02)
Table I. Patient, donor and transplant characteristics of the study population
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the complete OPTN model are available upon
request. 
Lower Medicare payments and shorter LOS were
observed in more recent transplant years in
a graded relationship. Other factors associated with
decreases in Medicare payments and LOS included
polycystic kidney disease (PKD) as cause of ESRD
and recipient or donor other than white or African-
American race. In general, the associated with
reduced LOS showed statistical significance while
the same variables were associated with reduced
payments compared to the reference groups but
without reaching statistical significance at the 95%
level. One exception was for transplant year of 1997
which also showed significantly reduced Medicare
payments. 
Charlson and Elixhauser comorbidities
The top 10 Charlson Comorbidites associated
with increased LOS consisted of a mix of OPTN and
non-OPTN recorded comordibities. The list included:
liver disease (moderate or severe), peptic ulcer
disease, congestive heart failure, cerebrovascular
disease, diabetes (with and without complications),
cancer, rheumatic disease, chronic pulmonary
disease and myocardial infarction. Six of the
Charlson comorbidities associated with highest
increase in Medicare payments were also on the
top 10 conditions associated with higher increases
in LOS. The other four were: AIDS/HIV, dementia,
peripheral vascular disease and mild liver disease
(Table III). No Charlson comorbidities were
associated with statistically significantly reduced
LOS or reduced payments. 
Top 10 Elixhauser comorbidities associated with
the largest increases in LOS were: lymphoma, other
neurological disorders, obesity, peptic ulcer disease
excluding bleeding, pulmonary disorders, hypo  -
thyroidisms, congestive heart failure, complicated
diabetes, alcohol abuse and fluid and electrolyte
disorders. Eight of these conditions were also among
the top 10 associated with highest increase in
Medicare payments. The two other conditions were
AIDS/HIV and uncomplicated diabetes (Table III).
Deficiency anemia (–1.5% [–2.7-0.2%]), and
complicated hypertension (–1.3 [–2.3-0.3]) were the
only factors associated with small and statistically
significant reductions in LOS. No Elixhauser
comorbidity was associated with statistically
significant reductions in payments. 
Variable N (%) (n = 24,963) Variable N (%) (n = 24,963)
Charlson comorbidities Cytomegalovirus sero-pairing
0 6,302 (25.25) Donor–/recipient– 2,892 (11.59)
1 7,446 (29.83) Donor–/recipient+ 5,468 (21.9)
2 4,938 (19.78) Donor+/recipient– 4,150 (16.62)
3 3,298 (13.21) Donor+/recipient+ 9,680 (38.78)
4 1,839 (7.37) Undiagnosed 2,773 (11.11)
5 793 (3.18) Delayed graft function 9,626 (38.56)
6 or more 347 (1.39) Induction immunosupression 12,026 (48.18)
Elixhauser comorbidities Discharge immunosupression (ref = tacrolimus
0 4,481 (17.95) and MMF)
1 3,294 (13.2) Cyclosporine and MMF 9,009 (36.09)
2 3,453 (13.83) Cyclosporine and azathioprine 3,638 (14.57)
3 3,415 (13.68) Tacrolimus and MMF 6,066 (24.3)
4 2,929 (11.73) Other 6,250 (25.04)
5 2,411 (9.66) Steroid Use 23,339 (93.49)
6 1,891 (7.58)
7 1,302 (5.22)
8 869 (3.48)
9 479 (1.92)
10 249 (1)
11 or more 190 (0.76)
Table I. cont.
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Sum of Charlson and Elixhauser comorbidities
Holding all other variables at mean values, each
additional Charlson comorbiditiy was associated
with a 2.94% (2.63-3.24) increase in LOS and $471
(330-612) additional Medicare payments per patient.
Each additional Elixhauser comorbidity carried
a 1.71% (1.5-1.9) increase in LOS and $277 (202-351)
additional Medicare payments.
Donation after cardiac death donor and
expanded criteria donor
Use of a DCD was associated with increases of
14% in LOS (9.18 to 10.5 days) and 5% in Medicare
payments ($27,524 to $29,018) . Use of ECD kidneys
showed 11 to 15% increased LOS (9.18 to 10.23 days
for donor age > 60 years and 9.18 to 10.5 days for
donor  age > 60 years and hypertension) and 1 to
3% increase in Medicare payments that was not
statistically significant ($504 for donor age > 60
years and $837 adding hypertension as donor
comorbidity).  
Discussion
Patients considered for transplantation are now
older and have more comorbidities than historically
[4]. Outcomes are also in general worse with less
than standard criteria donor (SCD) kidneys which
are used with increasing frequency. However,
transplantation of older, sicker patients with less
than SCD kidneys has been shown to be more cost-
effective than remaining on dialysis [17, 18]. Given
these trends, it is important to study the
associations between  pre-transplant  comorbidities
and organ quality with transplant procedure LOS
and payments. 
We confirmed previously reported OPTN factors
associated with higher Medicare payments or LOS,
such as longer duration of dialysis before transplant,
African American race, and use of a DCD [2, 8]. Type
I diabetes as cause of ESRD was the leading factor
associated with highest LOS and the second one
associated with higher Medicare payments. Use of
an ECD was previously found not to influence LOS
and hospital charges [3], or not strongly influencing
Medicare payments [1]. However, other studies
indicate that use of an ECD is associated with
inadequate payment [1] and longer LOS [2]. We
observed that use of a DCD is among the most
important factors associated with higher LOS and
we also found the use of an ECD to be among the
top individual contributors to LOS growth. The
associations for ECD and DCD are more likely
related to the higher rate of DGF associated with
these organs, which will require more dialysis and
therefore cost more to the transplant center [19].
Regarding OPTN and commonly considered
comorbidities in single center studies, our models
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confirmed previous findings. In effect, longer LOS
was associated with obesity, COPD and
cerebrovascular disease as previously reported in
a single center study [8]. These factors were not
among those most importantly associated with
transplant LOS. Other OPTN reported comorbidities
were shown to be associated with higher LOS or
Medicare payments either in their OPTN recorded
version or in the Charlson or Elixhaser relevant
measure (diabetes, myocardial infraction, cerebro  -
vascular disease and obesity). Some non-OPTN
reported comorbidities were also among the top
contributors to LOS and payments, among them
liver disease, cancer, AIDS/HIV, dementia and peptic
ulcer disease. Higher costs associated with certain
comorbidities are probably reflecting higher rates
of early complications leading to longer length of
stay or more resource intensive care associated
with the comorbid diseases. 
Each additional Charlson and Elixhauser
comorbidity increased both LOS and Medicare
payments and the same was observed for ECD or
DCD kidneys, Further analyses should explore if
there is a need of increased payments based on
comorbid disease or organ quality in order to
preserve the financial viability of kidney transplan  -
tation to more severe patients or when using ECD
or DCD kidneys. Actual hospital cost data, which
were not available in this sample would be needed
to answer that question, 
There are a number of strengths in this research.
We add to current knowledge by examining a large
number of comorbidities. We also used a multilevel
regression method that takes into account potential
error correlation between patients in the same
centers. Finally, our sample size expands the
generalizabiliy of previous work, which relied on
single center information.
This study had also some limitations. Selection
bias may have occurred because the study sample
is restricted to Medicare patients receiving
transplants from deceased donors with at least
a year on dialysis and the sample may differ for
patients who are privately insured. Comorbidity and
other model information may have retained some
level of measurement error. We expect that the bias
would result in conservative estimates. 
In conlusion, in this paper we expanded the
knowledge of the associations between
comorbidities and transplant procedure LOS and
Medicare payments beyond known OPTN recorded
factors. Further study of associations of pre-
transplant comorbidities with potential inadequate
payments for transplantation warrants consi  -
deration. Future work should also examine
subtypes of costs, including cost of immuno  -
suppressive regimens. International research should
also be pursued. Successful projects aimed at
reducing population health risks are known in
developing and developed countries [20], and
interventions aimed at improving the cost-
effectiveness of care should also be pursued in
groups with important diseases such as chronic
kidney disease including transplant recipient. The
impact of comborbidities on reimbursement, LOS
and transplant finances will depend on local
practice, outcomes and reimbursement systems
and further studies should be conducted to confirm
these associations and design appropriate
interventions.
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